Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada approves Cardiac Science's Powerheart:

This article was originally published in Clinica

Executive Summary

Cardiac Science has received the go-ahead to market its Powerheart hospital bedside defibrillator-monitor in Canada. The fully automatic device detects the onset of a life-threatening arrhythmias and delivers defibrillation in seconds without the aid of hospital staff. The product is already cleared for sale in Australia, Europe and in the US. The Irvine, California-based company says it began marketing the device in early 2000 since when, it has generated around $4.2 million in revenue based on the sale of 734 Powerheart systems and related accessories.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT070350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel